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BACKGROUND With improved percutaneous coronary intervention (PCI) techniques,
PCI has emerged to be a safe option for revascularization with good long term out-
comes in selected patients with unprotected left main coronary artery (uLMCA) le-
sions. Overexpansion beyond nominal size is a common procedure to ensure
adequate stent apposition during left main stenting to improve clinical outcome.
However there is limited data concerning the feasibility and safety of aggressive post
dilation of metallic stent platforms during left main stenting to achieve apposition
and reduce focal underexpansion.
OBJECTIVES The objectives of this study are to investigate if overexpansion can be
achieved beyond the recommended stent expansion limit for a 4.0mm metallic stent
and to compare different expansion techniques to achieve optimal apposition and
study the effect of overexpansion on the mechanical performance of the stent.
METHODS We performed bench testing to measure the effect of overexpansion on the
stent performance of thin strut (74mm) 4.0 mm drug eluting platinum chromium
stents (DES) (Synergy IITM, Boston Scientiﬁc, Natwick, MA, USA) in silicon phantom
models of 6 mm diameter. We tested the stents in the following 5 models; using a
6.0 mm balloon with Proximal Optimisation Technique (POT) at low (nominal)
pressure of 6 atm (Group 1- POT-LP); and rated burst pressure (RBP) of 14 atm (Group
2- POT-RBP); Final Kissing Balloon Dilation (FKBD) methods using relatively under-
sized (‘US’) 3.5mm and 4.0mm balloons at RBP (Group 3 FKBD-US); FKBD using
adequately sized 4.0mm and 5.0mm balloons at low pressure (Group 4- FKBD-LP) and
ﬁnally at RBP (Group 5- FKBD- RBP).
RESULTS The platinum chromium stents 4.0mm stent reached an outer diameter of
only 5.1mm by using a 6.0 mm balloon at 6 atm. Further postdilatation with higher
pressures (14 atm) resulted in a stent outer diameter of 6.0mm, demonstrating a
safety margin above the designated expansion limit. Simultaneous kissing with un-
dersized balloon diameters resulted in a high ellipticity index and importantly mal-
apposition. Using correctly sized balloons, stent area improved but ellipticity
remained and malapposition was less but still higher compared to POT-LP and
POT-RBP.
CONCLUSIONS Our study shows that the thin strut platinum chromium 4.0mm stents
can be safely expanded with the use of POT beyond the overexpansion limit of
5.75mm with optimal stent apposition and performance. Proximal optimisation using
adequately sized balloons and high pressure is advised to achieve optimal outcome in
left main stenting.CRT-154
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BACKGROUND Interventions of the left main coronary artery are complex and require
high degree of technical skills. Intravascular ultrasound (IVUS) can aid interventions
of the left main coronary artery. We performed this meta-analysis to assess the efﬁ-
cacy of use of IVUS compared to angiographic-guided PCI.
METHODS Electronic search of PubMed, EBSCO and Google Scholar databases was
done to identify studies of IVUS guided left main interventions. Pooled meta-analysis
of major adverse cardiac events (MACE), cardiac death, myocardial infarction (MI),
target vessel revascularization (TVR), target lesion revascularization (TLR) and stent
thrombosis was performed using Comprehensive Meta-analysis 2 software. Mantel-
Haenszel random effects model was used to compute the odds ratio (OR) for the
above outcomes with and without the use of IVUS.
RESULTS A total of 4 studies with 2607 patients were identiﬁed that compared left
main interventions done using with and without IVUS guidance. Interventions were
done using IVUS in 1576 and angiographic-guided interventions were performed in
1031 patients. The risk of MACE with the use of IVUS guided intervention was 0.64
(95% CI: 0.49 - 0.83). The use of IVUS decreased cardiovascular death (OR 0.37; 95%
CI: 0.23 -0.6) and MI (OR 0.69; 95% CI: 0.51 - 0.92). IVUS use in left main intervention
had a trend towards lower TVR (OR 0.66; 95% CI: 0.27 - 2.49), TLR (OR 0.74; 95% CI
0.5 - 1.09) and stent thrombosis (OR 0.26; 0.07 - 1.04).
CONCLUSION The use of IVUS for left main interventions is associated with 36%
lower risk of MACE, 31% lower risk of repeat MI and 63% lower risk of cardiovascular
death. The above ﬁndings suggest major outcomes beneﬁt with the use of IVUS for
left main interventions.OTHER
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OBJECTIVE he aim of this registry is to evaluate the clinical performance of a new
generation Sirolimus eluting stent system (Orsiro) in a large patient population in
standard clinical care.
The Orsiro is a unique hybrid solution that combines passive and active compo-
nents. PROBIO passive coating encapsulates the stent and minimizes interaction
between the metal stent and surrounding tissue. BIOlute active coating contains a
highly biocompatible and biodegradable polymer.
METHODS Between August 2011 and March 2012, 1,356 subjects were enrolled
consecutively in this international, multicentric BIOFLOW-III all-comers registry us-
ing the Orsiro Sirolimus eluting stent.
Primary endpoint is Target Lesion Failure (TLF) at twelve months follow-up. Pre-
speciﬁed subgroups were diabetes, small vessels, chronic total occlusion and
